The Diabetes Atherosclerosis Intervention Study (DAIS) with patients of T2DM treated with micronized fenofibrate for an average of 38 months suggested that fenofibrate significantly reduced the worsening of albumin excretion, which was associated with reduced progression of normal albumin excretion to microalbuminuria [24]. The investigators concluded that the improvement in lipid profile with fenofibrate in patients with T2DM was associated with reduced progression to microalbuminuria.